# Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

Source: https://onco.cc/trials/nct07561775/  
OnCo record `nct07561775` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab and S-1 in gallbladder cancer and other biliary tract cancers, run by Xingjun Guo, not yet recruiting.

## Summary

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma is a phase 2 interventional study registered as NCT07561775 by Xingjun Guo, with a registry enrolment figure of 40 participants, started 2026-04-21 and due to reach its primary completion in 2028-01-01. Interventions recorded: Adebrelimab, S-1. Conditions listed: Cholangiocarcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07561775
- Phase: 2
- Setting: A Single-Arm, Exploratory Clinical Study of Adebrelimab Combined With S-1 in Patients With Resected Cholangiocarcinoma
- Sponsor: Xingjun Guo
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07561775: https://clinicaltrials.gov/study/NCT07561775

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07561775.json